X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
PTG-300 (rusfertide) is a hepcidin inhibitor, which is being evaluated in the Phase III clinical trial studies with patients for the treatment of Polycythemia Vera.
Lead Product(s): Rusfertide
Therapeutic Area: Oncology Product Name: PTG-300
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2024
Details:
The collaboration aims to support the development of PTG-300 (rusfertide) for the treatment of Polycythemia Vera. The protagonist will be responsible for research and development through the completion of the Phase 3 clinical trial and U.S. regulatory approval.
Lead Product(s): Rusfertide
Therapeutic Area: Oncology Product Name: PTG-300
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: Undisclosed Upfront Cash: $300.0 million
Deal Type: Collaboration March 18, 2024
Details:
The collaboration aims to support the development of PTG-300 (rusfertide) for the treatment of Polycythemia Vera. The protagonist will be responsible for research and development through the completion of the Phase 3 clinical trial and U.S. regulatory approval.
Lead Product(s): Rusfertide
Therapeutic Area: Oncology Product Name: PTG-300
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: Undisclosed Upfront Cash: $300.0 million
Deal Type: Collaboration January 31, 2024
Details:
Under the Agreement, Janssen is conducting Phase 2b trial of JNJ-2113 (formerly known as PN-235), a first-in-class targeted oral peptide designed to selectively block the IL-23 receptor, in moderately to severely active ulcerative colitis.
Lead Product(s): JNJ-2113
Therapeutic Area: Gastroenterology Product Name: JNJ-2113
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: JANSSEN BIOTECH
Deal Size: $987.5 million Upfront Cash: $50.0 million
Deal Type: Licensing Agreement December 13, 2023
Details:
JNJ-2113 is a first and only targeted oral peptide that is designed to selectively block the IL-23 receptor. It is under clinical development for the treatment of moderate-to-severe psoriasis.
Lead Product(s): PN-235
Therapeutic Area: Dermatology Product Name: JNJ-2113
Highest Development Status: Phase IIIProduct Type: Peptide
Recipient: Johnson & Johnson Innovative Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 27, 2023
Details:
The collaboration aims for the co-development and commercialization of JNJ-2113, a novel, first and only oral IL-23 receptor antagonist peptide, in patients with moderate-to-severe psoriasis.
Lead Product(s): PN-235
Therapeutic Area: Dermatology Product Name: JNJ-2113
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine
Deal Size: $990.0 million Upfront Cash: $50.0 million
Deal Type: Collaboration November 01, 2023
Details:
JNJ-2113 (formerly known as PN-235) is the first-and only-in-class oral IL-23 receptor antagonist as a potential oral targeted therapy for plaque psoriasis.
Lead Product(s): PN-235
Therapeutic Area: Dermatology Product Name: JNJ-2113
Highest Development Status: Phase IIProduct Type: Peptide
Recipient: Johnson & Johnson Innovative Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 04, 2023
Details:
The net proceeds intends to fund the continued clinical development and pre-commercialization activities associated with PTG-300 (rusfertide), an injectable hepcidin mimetic in development for the treatment of polycythemia vera and other blood disorders.
Lead Product(s): Rusfertide
Therapeutic Area: Oncology Product Name: PTG-300
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: J.P. Morgan Securities LLC
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 04, 2023
Details:
PTG-300 (rusfertide) is a hepcidin-mimetic that helps reduce iron availability to help achieve hematocrit control and decrease erythropoiesis in patients with polycythemia vera (PV) without the need for periodic therapeutic phlebotomy.
Lead Product(s): Rusfertide
Therapeutic Area: Oncology Product Name: PTG-300
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 15, 2023
Details:
JNJ-2113 (formerly known as PN-235) is the first-and only-in-class oral IL-23 receptor antagonist as a potential oral targeted therapy for plaque psoriasis.
Lead Product(s): PN-235
Therapeutic Area: Dermatology Product Name: JNJ-2113
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 07, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
